Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lulizumab Pegol Phase 2 in SLE
NCT02265744Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2014
- Primary completion
- Oct 2017
- Modality
- Antibody Fragments, Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 2 trial of lulizumab pegol in systemic lupus erythematosus (SLE), sponsored by Bristol Myers Squibb. Started Nov 2014; status: completed.
02
Drugs
lulizumab pegol
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02265744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265744.